Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Timing matters: automatic rebalancing should occur as your allocations drift beyond set thresholds.
18,157 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Palantir Technologies has had a wild ride. If you’re wondering should palantir technologies stock be bought under $14...
As quantum tech moves from lab to real-world use, two stocks stand out for 2026. This guide explains why IonQ and IBM...
On March 2, energy and defense names spearheaded gains as oil jumped, while travel and leisure stocks softened. This ...
A senior executive at AtriCure recently sold 5,000 shares, prompting questions about what this insider move means for...
As Berkshire Hathaway's leadership evolves, investors wonder if berkshire hathaway greg abel has echoed Warren Buffet...
Alphabet’s billion flex is more than just cash. It’s a strategic playbook that powers buybacks, AI investments, and l...
SpaceX headlines grab attention, but smart investors look for durable earnings growth in established aerospace player...
Conagra (CAG) faces a pivotal year as 2026 earnings hinge on pricing, cost control, and portfolio focus. This analysi...
Looking for biotech growth with real upside? This piece breaks down two innovative biotech stocks that could deliver ...
February brought a notable rally for shares altria group stock. This article breaks down the drivers, the risks, and ...
Investors are watching a handful of tech names retreat despite strong long term potential. This guide explains how be...